ClinicalTrials.gg
Not yet recruitingNCT07093021MARES2Updated Jul 30, 2025

Mitigating Chronic Respiratory Disease Through the Lens of Multimorbidity

An observational study in Chronic Obstructive Pulmonary Disease (COPD), Asthma and Preserved Ratio Impaired Spirometry, sponsored by University College, London. Not yet recruiting at 2 sites in Brazil. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by University College, London · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
1,000
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London — 4 open to participants now, 4 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University College, London.

Started
2025
with 3 others
Observational
9 of 14
4 open now
Registered
13th of 14
by date

Among the 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London, this one is one of 4 that started in 2025, is one of 9 observational ones, and was the 13th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

4 of the 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London, or all of them as a file.
02

Study summary

The investigators aim to evaluate whether it is feasible for healthcare professionals to implement a case-finding tool to identify individuals at high risk for chronic respiratory diseases (CRDs) during routine care for non-communicable diseases (NCDs) in primary healthcare services in Brazil.

The investigators will complete a cross-sectional observational study involving 20 healthcare professionals (physicians, physiotherapists, community health agents, and nurses) from five primary healthcare services who will apply the COLA-6 tool during routine NCD care. A total sample of 1,000 patients is expected. Qualitative interviews will be conducted with healthcare professionals to explore barriers and facilitators to implementing COLA-6 in clinical practice.

Read the detailed description

The investigators will assess the feasibility of healthcare professionals implementing the COLA-6 case-finding tool to identify individuals at high-risk of chronic respiratory diseases (CRDs) in primary health care (PHC) settings for non-communicable disease (NCD) care in Brazil. CRDs include asthma and chronic obstructive pulmonary disease (COPD). The COLA-6 ("COPD in Low- and Middle-Income Countries Assessment") is a validated and simple case-finding strategy designed to identify individuals at risk for CRDs in low- and middle-income country (LMIC) settings.

The study will be carried out in PHC services, including Basic Health Units (BHUs) and Family Health Units (FHUs), located in the municipalities of São Carlos and São Paulo, both in the state of São Paulo, Brazil.

The study will include two main participant groups:

(1) individuals with one or more NCDs who receive care from PHC services, and (2) healthcare professionals (HCPs) working in these settings.

HCPs will be recruited from BHUs and FHUs in São Carlos and São Paulo.

Eligible patients with NCDs will be identified by HCPs during routine appointments for NCDs (e.g., hypertension, diabetes, etc.). All participants will provide written informed consent.

The study comprises two phases:

Phase 1 - Implementation of COLA-6:

Application of the COLA-6 tool: After receiving prior training from the research team, HCPs at the BHUs and FHUs will identify potentially eligible individuals with NCDs who attend PHC services and will administer the COLA-6 tool as part of their routine care. Participants identified as being at high risk for CRDs based on the COLA-6 results will receive a leaflet with basic guidance on accessing diagnostic and treatment services for respiratory conditions.

Fidelity Monitoring: Selected administration of the COLA-6 tool by each HCP will be observed by the research team to ensure adherence to protocol.

Phase 2 - Evaluation of Implementation:

Upon completion of the 50 COLA-6 applications, HCPs will participate in qualitative interviews conducted by the research team to explore the barriers and facilitators to implementation in routine PHC settings.

Interviews will be audio-recorded, transcribed verbatim, and anonymized prior to analysis. The questions will address feasibility aspects such as the time required to complete the questionnaire, difficulties encountered, clarity of the questions, uncertainties during integration of the tool into the work routine, and patient receptiveness.

The research team will work in five BHU/FHUs, with five HCPs at each unit, each administering COLA-6 to fifty patients.

Patients identified as being at high risk for CRDs will be asked if they can be contacted for future research.

Descriptive statistics will be used to characterize patient and professional samples. Quantitative analysis of fidelity data will report categorical variables as frequencies (percentages). The qualitative analysis of the interviews will follow Braun and Clarke, which consists of six phases: 1) Familiarization with the data set; 2) Coding; 3) Generation of initial themes; 4) Development and review of themes; 5) Refinement, definition and naming of themes; and 6) Writing.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Preserved Ratio Impaired Spirometry

Keywords

  • case-finding
  • chronic obstructive pulmonary disease
  • asthma
  • multi-morbidity
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  1. HCPs providing NCD care in PHC services in Brazil.
  2. Patients attending for NCD care in PHC services in Brazil.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

HCP: providing care to people with NCDs in PHC settings in Brazil. PATIENTS: attending for NCD care at a PHC setting in Brazil.

Exclusion criteria

Exclusion Criteria:

HCP: not received training to deliver COLA-6.

PATIENTS:

  • not provided
  • clinically unstable in the past month
  • current pregnancy
  • active tuberculosis or being on treatment for tuberculosis
  • cognitive impairment that would prevent understanding of the case-finding tool
  • to lung function testing.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Barriers and facilitators to implementing the COLA-6 case-finding tool.

    Barriers and facilitators to implementing the COLA-6 case-finding tool, assessed at qualitative interviews.

    Time frame: At study completion: qualitative interviews will be completed after each HCP has completed 50 uses of COLA-6.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — We have no plans to share individual responses from qualitative interviews.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Aug 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Jul 30, 2025
StartEst.
Aug 2025
Primary completionEst.
Aug 2026
CompletionEst.
Dec 2026
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07093021
Collaborators
Universidade Federal de Sao Carlos
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Aug 2025 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 30, 2025

Study contacts

Viviane Castello
Contact
vivianecastello@ufscar.br
(+5516) 99992 4777
John R Hurst, PhD FRCP
principal investigator · University College London Hospitals
Renata G Mendes, DFisio
principal investigator · Federal University of Sao Carlos (UFScar), Brasil

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion